CN103768307A - Traditional Chinese medicine for treating post-stroke limb numbness and preparation method thereof - Google Patents
Traditional Chinese medicine for treating post-stroke limb numbness and preparation method thereof Download PDFInfo
- Publication number
- CN103768307A CN103768307A CN201410046040.XA CN201410046040A CN103768307A CN 103768307 A CN103768307 A CN 103768307A CN 201410046040 A CN201410046040 A CN 201410046040A CN 103768307 A CN103768307 A CN 103768307A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- caulis
- herba
- ramulus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 99
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 231100000862 numbness Toxicity 0.000 title abstract description 15
- 238000011282 treatment Methods 0.000 claims abstract description 49
- 229940079593 drug Drugs 0.000 claims abstract description 32
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 241001522129 Pinellia Species 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 39
- 208000006011 Stroke Diseases 0.000 claims description 37
- 206010008190 Cerebrovascular accident Diseases 0.000 claims description 34
- 210000002435 tendon Anatomy 0.000 claims description 31
- 239000000843 powder Substances 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 241000756943 Codonopsis Species 0.000 claims description 17
- 241000237903 Hirudo Species 0.000 claims description 17
- 241000237636 Pheretima Species 0.000 claims description 17
- 241000131808 Scolopendra Species 0.000 claims description 17
- 241000522620 Scorpio Species 0.000 claims description 17
- 239000009636 Huang Qi Substances 0.000 claims description 15
- 239000009490 scorpio Substances 0.000 claims description 15
- 239000000706 filtrate Substances 0.000 claims description 10
- 239000000284 extract Substances 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 5
- 239000004615 ingredient Substances 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- 238000010298 pulverizing process Methods 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- 241000726094 Aristolochia Species 0.000 claims description 2
- 241000545442 Radix Species 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 210000003414 extremity Anatomy 0.000 abstract description 29
- 239000008280 blood Substances 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 17
- 208000034783 hypoesthesia Diseases 0.000 abstract description 17
- 210000004369 blood Anatomy 0.000 abstract description 16
- 208000002193 Pain Diseases 0.000 abstract description 11
- 208000024891 symptom Diseases 0.000 abstract description 6
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 5
- 208000026435 phlegm Diseases 0.000 abstract description 5
- 206010019468 Hemiplegia Diseases 0.000 abstract description 4
- 230000003213 activating effect Effects 0.000 abstract description 4
- 241000045403 Astragalus propinquus Species 0.000 abstract 1
- 241000258920 Chilopoda Species 0.000 abstract 1
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract 1
- 241000007126 Codonopsis pilosula Species 0.000 abstract 1
- 241001166194 Geranium wilfordii Species 0.000 abstract 1
- 241000545744 Hirudinea Species 0.000 abstract 1
- 208000004044 Hypesthesia Diseases 0.000 abstract 1
- 241000488974 Loranthus Species 0.000 abstract 1
- 241000243684 Lumbricus Species 0.000 abstract 1
- 241000239226 Scorpiones Species 0.000 abstract 1
- 241000157352 Uncaria Species 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 230000001914 calming effect Effects 0.000 abstract 1
- 230000003071 parasitic effect Effects 0.000 abstract 1
- 239000009910 sargent gloryvine Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 230000035876 healing Effects 0.000 description 12
- 230000007812 deficiency Effects 0.000 description 7
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 5
- 241000345998 Calamus manan Species 0.000 description 4
- 208000029078 coronary artery disease Diseases 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 210000003141 lower extremity Anatomy 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 235000012950 rattan cane Nutrition 0.000 description 4
- -1 tie up main plain E Natural products 0.000 description 4
- 210000001364 upper extremity Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 201000005577 familial hyperlipidemia Diseases 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 208000006750 hematuria Diseases 0.000 description 2
- 208000021760 high fever Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010003062 Apraxia Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 239000003390 Chinese drug Substances 0.000 description 1
- 206010009866 Cold sweat Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 206010016326 Feeling cold Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033546 Pallor Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001769 paralizing effect Effects 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of medicines, and particularly relates to a traditional Chinese medicine for treating numbness of limbs after stroke and a preparation method thereof. The traditional Chinese medicine for treating post-stroke limb numbness is prepared from the following traditional Chinese medicine raw materials in parts by weight: 50-70 parts of astragalus membranaceus, 15-25 parts of codonopsis pilosula, 7-13 parts of lumbricus, 7-13 parts of leech, 7-13 parts of scorpion, 7-13 parts of centipede, 25-35 parts of geranium wilfordii, 15-25 parts of caulis spatholobi, 15-25 parts of sargentgloryvine stem, 7-13 parts of pinellia ternate, 15-25 parts of parasitic loranthus, 10-25 parts of ramulus mori, 7-13 parts of herba aristolochiae, 7-13 parts of caulis sinomenii, 7-13 parts of caulis trachelospermi, 7-13 parts of uncaria and 7-13 parts of cassia twig. The traditional Chinese medicine has the effects of tonifying qi and activating blood, calming wind and reducing phlegm, dispelling wind and removing dampness, and dredging collaterals and relieving pain, is used for treating numbness of limbs after stroke with symptoms of limb numbness, pain, hemiplegia and the like, and has the advantages of quick response, short treatment course, safety and reliability.
Description
Technical field
The invention belongs to medical technical field, be specifically related to a kind of Chinese medicine for the treatment of numb limbs and tense tendons after apoplexy and preparation method thereof.
Background technology
Apoplexy is the general designation of Chinese medicine to acute cerebrovascular disease.It is suddenly to faint, syncope, distortion of commissure, dysphonia and occur that hemiplegia is a class disease of cardinal symptom occur together, because primary disease sickness rate is high, mortality rate is high, disability rate is high, relapse rate is high and complication is many, so medical circle is listed as its same coronary heart disease, cancer one of three large diseases that threaten human health.After apoplexy, numb hand and foot is comparatively common apoplexy sequela, and the end of the limbs of patient's Ipsilateral, especially limbs as the face skin of cheek of finger, toe or hemiplegia side has ant to climb sensation, or have prickling sensation, or it is blunt to show as irritant reaction.Numb normal relevant with Changes in weather, weather drastic shift, humid, or rain in the situations such as front and back, cold weather, it is especially obvious that numbness is felt; Be characterized in course of disease length, weak curative effect, take effect slowly, patient suffering is larger, and treatment specific aim is poor, causes great impact to patient's daily life.
Summary of the invention
In order to solve above-mentioned technical problem, the invention provides a kind of Chinese medicine for the treatment of numb limbs and tense tendons after apoplexy and preparation method thereof.Can effectively solve by the problem of wind-induced numb limbs and tense tendons, safe and reliable, short treating period, instant effect.
The present invention realizes by following technical scheme:
A Chinese medicine for the treatment of numb limbs and tense tendons after apoplexy, is made up of the raw material of Chinese medicine medicine of following weight portion:
Radix Astragali 50-70 part, Radix Codonopsis 15-25 part, Pheretima 7-13 part, Hirudo 7-13 part, Scorpio 7-13 part, Scolopendra 7-13 part, Herba Erodii 25-35 part, Caulis Spatholobi 15-25 part, Caulis Sargentodoxae 15-25 part, Rhizoma Pinelliae 7-13 part, Herba Taxilli 15-25 part, Ramulus Mori 10-25 part, Herba Aristolochiae 7-13 part, Caulis Sinomenii 7-13 part, Caulis Trachelospermi 7-13 part, Ramulus Uncariae Cum Uncis 7-13 part, Ramulus Cinnamomi 7-13 part.
Preferably, the Chinese medicine of numb limbs and tense tendons after above-mentioned treatment apoplexy, is made up of the raw material of Chinese medicine medicine of following weight portion:
Radix Astragali 55-65 part, Radix Codonopsis 17-23 part, Pheretima 8-12 part, Hirudo 8-12 part, Scorpio 8-12 part, Scolopendra 8-12 part, Herba Erodii 27-33 part, Caulis Spatholobi 17-23 part, Caulis Sargentodoxae 17-23 part, Rhizoma Pinelliae 8-12 part, Herba Taxilli 17-23 part, Ramulus Mori 12-18 part, Herba Aristolochiae 8-12 part, Caulis Sinomenii 8-12 part, Caulis Trachelospermi 8-12 part, Ramulus Uncariae Cum Uncis 8-12 part, Ramulus Cinnamomi 8-12 part.
Preferred, the Chinese medicine of numb limbs and tense tendons after above-mentioned treatment apoplexy, is made up of the raw material of Chinese medicine medicine of following weight portion:
60 parts of the Radixs Astragali, 20 parts of Radix Codonopsis, 10 parts of Pheretimas, 10 parts of Hirudos, 10 parts of Scorpios, 10 parts of Scolopendras, 30 parts of Herba Erodiis, 20 parts of Caulis Spatholobis, 20 parts of Caulis Sargentodoxae, 10 parts of the Rhizoma Pinelliaes, 20 parts of Herba Taxillis, 15 parts of Ramulus Moris, 10 parts of Herba Aristolochiaes, 10 parts of Caulis Sinomeniis, 10 parts of Caulis Trachelospermis, 10 parts of Ramulus Uncariae Cum Uncis, 10 parts of Ramulus Cinnamomi.
The Chinese medicine of numb limbs and tense tendons after above-mentioned treatment apoplexy, the dosage form of this Chinese medicine is oral formulations.
Preferably, the Chinese medicine of numb limbs and tense tendons after above-mentioned treatment apoplexy, the dosage form of this Chinese medicine is capsule, tablet.
After above-mentioned treatment apoplexy, the preparation method of the Chinese medicine of numb limbs and tense tendons, comprises the steps:
(a) Radix Astragali, Radix Codonopsis, Herba Erodii, Caulis Spatholobi, Caulis Sargentodoxae, the Rhizoma Pinelliae, Herba Taxilli, Ramulus Mori, Herba Aristolochiae, Caulis Sinomenii, Caulis Trachelospermi, Ramulus Uncariae Cum Uncis, Ramulus Cinnamomi decocts with water 2 times, the 8-10 that amount of water is drug weight for the first time doubly, decoct 1.5-2.5 hour, the 4-6 that amount of water is drug weight for the second time doubly, decoct 1-2 hour, collecting decoction, filter, filtrate is condensed into the thick paste that relative density is 1.16-1.19, add ethanol make containing alcohol amount be 70%, leave standstill 8 hours, filter, 60 ℃ of concentrating under reduced pressure of filtrate reclaim ethanol, then medicine is condensed into thick paste, 60 ℃ of drying under reduced pressure are crossed 100 mesh sieves after pulverizing, be prepared into extract powder,
(b) Pheretima, Hirudo, Scorpio, Scolopendra superfine powder are broken into the drug powder of superfine powder particle size range 5-45 μ m;
(c) drug powder that medicated powder step (a) being obtained and step (b) make mixes, and obtains middle the effective elements of the medicine of the present invention;
(d) effective ingredient of step (c) gained adds pharmaceutically acceptable adjuvant to make preparation.
Described pharmaceutically acceptable adjuvant is selected from: sucrose, starch, magnesium stearate, mannitol, sorbitol, sorbic acid or potassium salt, sodium pyrosulfite, sodium sulfite, sodium thiosulfate, cysteine hydrochloride, TGA, methionine, vitamin A, vitamin C, tie up main plain E, vitamin D, azone, EDETATE SODIUM, Ethylenediaminetetraacetic Acid Calcium Salt, the alkali-metal carbonate of monovalence, acetate, phosphate or its aqueous solution, hydrochloric acid, acetic acid, sulphuric acid, phosphoric acid, aminoacid, sodium chloride, potassium chloride, sodium lactate, xylitol, maltose, glucose, fructose, dextran, glycine, lactose, mannitol, silicon derivative, cellulose and derivant thereof, alginate, gelatin, polyvinylpyrrolidone, glycerol, propylene glycol, ethanol, polysorbate60～80, department class～80, Cera Flava, lanoline, liquid paraffin, hexadecanol, gallate ester, fine jade, triethanolamine, basic amino acid, carbamide, allantoin, calcium carbonate, calcium bicarbonate, surfactant, Polyethylene Glycol, cyclodextrin, β～cyclodextrin, phospholipid material, Kaolin, Pulvis Talci, calcium stearate etc.
Preferably, after above-mentioned treatment apoplexy in the preparation method of the Chinese medicine of numb limbs and tense tendons, in described step (a), amount of water is drug weight 9 times for the first time, decocts 2 hours, and amount of water is drug weight 5 times for the second time, decocts 1.5 hours.
After treatment apoplexy of the present invention in the raw material of Chinese medicine medicine of numb limbs and tense tendons, each herbal medicine is the Chinese medicine of recording in 2005 editions one of one of Chinese Pharmacopoeia version in 2010 or Chinese Pharmacopoeia.
Chinese medicine of the present invention, there is benefiting QI for activating blood circulation, relieve dizziness, high fever, infantile convulsions, epilepsy, etc. reduce phlegm, effect of expelling wind and removing dampness, removing obstruction in the collateral to relieve pain, for the numb limbs and tense tendons after apoplexy, disease sees that disease sees numb limbs and tense tendons, pain, hemiplegia etc.
Apoplexy is clinical common harm middle-aged and elderly people life and affects one of three large diseases of quality of life.Its being seen numb limbs and tense tendons is meciless brings endless worries to patient especially.Apoplexy is divided into middle warp, appoplexy involving the collateral, apoplexy involving ZANG-organ, apoplexy involving FU-organ by motherland's medical science.Thinking that limbs numbness of the skin is meciless mostly is due to appoplexy involving the collateral.Meridians appoplexy involving the collateral is acral, and general medicine is difficult to reach, therefore this disease course of disease is long, weak curative effect, takes effect slow.
On the basis of discussing at ancient Chinese medicine doctor, applicant, in conjunction with clinical experience, thinks that paralytic's group of people at high risk mostly is old age or presenium patient, over fifty and half of YIN QI consumed.Qi being the governor of blood.The normal operation of blood, depends on the normal operation of gas, blood being the material foundation of QI, blood can carry QI, QI and blood homology.Apoplexy is take blood stasis as main pathogenesis, and blood stasis also runs through primary disease all the time.Internal organs hypofunction and vigour are from declining, and postapoplectic special circumstances in addition, must consume and hinder healthy energy, and the state of body QI and blood deficiency is increased the weight of, and of a specified duration can develop as syndrome of blood stasis due to qi deficiency, because of the stagnant pathological change of the unable promoting the circulation of blood hyperamization of deficiency of vital energy clots absorbing.A variety of causes divides in the blood stasis causing and stops, and retardance venation, had both increased the weight of the retardance of mechanism of qi, can be further as heavy stagnation of QI-blood, and this is the main pathogenesis of stroke in convalescent stage just also.Internal organs hypofunction, insufficiency of the spleen transporting is unable, raw retardance meridians in phlegm-damp, old caused by liver and kidney deficiency in addition, liver governing tendons arteries and veins, muscle arteries and veins loses supports, and sees numb limbs and tense tendons or alters pain, and half body apraxia, speech are not smoothgoing puckery, and the disease of the deficiency of vital energys such as deficiency of QI with disinclination to talk, has again the performance of paralysis, blood stasis.Control and work as benefiting QI for activating blood circulation, expelling wind and removing dampness, removing obstruction in the collateral to relieve pain.After the treatment apoplexy of invention in the Chinese prescription of numb limbs and tense tendons, the Radix Astragali, Radix Codonopsis strongly invigorating primordial QI, Pheretima, Hirudo, Caulis Spatholobi, Caulis Sargentodoxae blood circulation promoting and blood stasis dispelling, the Rhizoma Pinelliae, Ramulus Uncariae Cum Uncis relieve dizziness, high fever, infantile convulsions, epilepsy, etc. and reduce phlegm, Scorpio, Scolopendra are searched wind, Herba Taxilli nourishing the liver and kidney, Ramulus Mori, Herba Aristolochiae, Caulis Sinomenii, Caulis Trachelospermi expelling wind and removing dampness removing obstruction in the collateral to relieve pain, Ramulus Cinnamomi tying-in is promoted blood circulation.All medicines share, and play altogether and there is benefiting QI for activating blood circulation, expelling wind and removing dampness, effect of removing obstruction in the collateral to relieve pain, is clinically mainly used in after apoplexy numb limbs and tense tendons after numb limbs and tense tendons, the especially Stroke In Aged of body void.After treatment apoplexy of the present invention, in the Chinese prescription of numb limbs and tense tendons, having used a large amount of rattan class medicines, is according to the analogy of image extracting draw in theory of Chinese medical science, get rattan class and be apt to away meridians, the network of the meridians end that can go directly, thereby the curative effect of raising medicine, make medicine instant effect, short treating period.
The invention has the advantages that:
(1) the invention provides the Chinese medicine of numb limbs and tense tendons after a kind of new treatment apoplexy, met clinical needs.In this Chinese prescription, having used a large amount of rattan class medicines, is according to the analogy of image extracting draw in theory of Chinese medical science, get rattan class and be apt to away meridians, and the network of the meridians end that can go directly, thus the curative effect of raising medicine makes medicine instant effect, short treating period.
(2) Chinese drug preparation of numb limbs and tense tendons after treatment apoplexy is become preparation by the present invention, both kept decoction to absorb fast, effective feature rapidly, overcome again decoction and taken front interim decoction, is long placed in easily mouldly to lose rotten shortcoming, and can covers the bitterness of Chinese medicine.Chinese medicine preparation Chinese crude drug of the present invention all extracts through refining, and volume-diminished is transported, carried, taking convenience.
(3) clinical test results shows, treatment group cure rate is 44%, and total effective rate is 96%: matched group cure rate is 14%, and total effective rate is 62%.Treatment group is compared with matched group, and both curative effects have significant difference (P<O.01).Wherein in the routine patient of matched group 50,1 the course for the treatment of healing person be 5 examples, 2 the course for the treatment of healing person reach 12 examples, three courses for the treatment of, healing person reached 22 examples; In the routine patient of matched group 50,1 the course for the treatment of healing person be 0 example, 2 the course for the treatment of healing person reach 3 examples, three courses for the treatment of, healing person reached 7 examples.
The specific embodiment
Below in conjunction with specific embodiment, the present invention is further described, so that those skilled in the art more understands the present invention, but does not therefore limit the present invention.
Embodiment 1
Prescription:
Radix Astragali 60g, Radix Codonopsis 20g, Pheretima 10g, Hirudo 10g, Scorpio 10g, Scolopendra 10g, Herba Erodii 30g, Caulis Spatholobi 20g, Caulis Sargentodoxae 20g, Rhizoma Pinelliae 10g, Herba Taxilli 20g, Ramulus Mori 15g, Herba Aristolochiae 10g, Caulis Sinomenii 10g, Caulis Trachelospermi 10g, Ramulus Uncariae Cum Uncis 10g, Ramulus Cinnamomi 10g.
Preparation method:
(a) Radix Astragali, Radix Codonopsis, Herba Erodii, Caulis Spatholobi, Caulis Sargentodoxae, the Rhizoma Pinelliae, Herba Taxilli, Ramulus Mori, Herba Aristolochiae, Caulis Sinomenii, Caulis Trachelospermi, Ramulus Uncariae Cum Uncis, Ramulus Cinnamomi decocts with water 2 times, amount of water is drug weight 9 times for the first time, decoct 2 hours, amount of water is drug weight 5 times for the second time, decoct 1.5 hours, collecting decoction, filter, filtrate is condensed into the thick paste that relative density is 1.16-1.19, add ethanol make containing alcohol amount be 70%, leave standstill 8 hours, filter, 60 ℃ of concentrating under reduced pressure of filtrate reclaim ethanol, then medicine is condensed into thick paste, 60 ℃ of drying under reduced pressure are crossed 100 mesh sieves after pulverizing, be prepared into extract powder,
(b) Pheretima, Hirudo, Scorpio, Scolopendra superfine powder are broken into the drug powder of superfine powder particle size range 5-45 μ m;
(c) drug powder that medicated powder step (a) being obtained and step (b) make mixes, and obtains middle the effective elements of the medicine of the present invention;
(d) effective ingredient of step (c) gained adds magnesium stearate, starch, makes 200 of capsules, every heavy 0.5g.
Usage and dosage: each 4, every day 3 times, one after each meal.Avoid pungent raw and cold diet.
Embodiment 2
Prescription:
Radix Astragali 55g, Radix Codonopsis 23g, Pheretima 8g, Hirudo 12g, Scorpio 8g, Scolopendra 12g, Herba Erodii 27g, Caulis Spatholobi 23g, Caulis Sargentodoxae 17g, Rhizoma Pinelliae 12g, Herba Taxilli 17g, Ramulus Mori 18g, Herba Aristolochiae 8g, Caulis Sinomenii 12g, Caulis Trachelospermi 8g, Ramulus Uncariae Cum Uncis 12g, Ramulus Cinnamomi 8g.
Preparation method:
(a) Radix Astragali, Radix Codonopsis, Herba Erodii, Caulis Spatholobi, Caulis Sargentodoxae, the Rhizoma Pinelliae, Herba Taxilli, Ramulus Mori, Herba Aristolochiae, Caulis Sinomenii, Caulis Trachelospermi, Ramulus Uncariae Cum Uncis, Ramulus Cinnamomi decocts with water 2 times, amount of water is drug weight 8 times for the first time, decoct 1.5 hours, amount of water is drug weight 4 times for the second time, decoct 1 hour, collecting decoction, filter, filtrate is condensed into the thick paste that relative density is 1.16-1.19, add ethanol make containing alcohol amount be 70%, leave standstill 8 hours, filter, 60 ℃ of concentrating under reduced pressure of filtrate reclaim ethanol, then medicine is condensed into thick paste, 60 ℃ of drying under reduced pressure are crossed 100 mesh sieves after pulverizing, be prepared into extract powder,
(b) Pheretima, Hirudo, Scorpio, Scolopendra superfine powder are broken into the drug powder of superfine powder particle size range 5-45 μ m;
(c) drug powder that medicated powder step (a) being obtained and step (b) make mixes, and obtains middle the effective elements of the medicine of the present invention;
(d) effective ingredient of step (c) gained adds magnesium stearate, starch, is pressed into 200, tablet, every heavy 0.5g.
Usage and dosage: each 4, every day 3 times, one after each meal.Avoid pungent raw and cold diet.
Embodiment 3
Prescription:
Radix Astragali 65g, Radix Codonopsis 17g, Pheretima 12g, Hirudo 8g, Scorpio 12g, Scolopendra 8g, Herba Erodii 33g, Caulis Spatholobi 17g, Caulis Sargentodoxae 23g, Rhizoma Pinelliae 8g, Herba Taxilli 23g, Ramulus Mori 12g, Herba Aristolochiae 12g, Caulis Sinomenii 8g, Caulis Trachelospermi 12g, Ramulus Uncariae Cum Uncis 8g, Ramulus Cinnamomi 12g.
Preparation method:
(a) Radix Astragali, Radix Codonopsis, Herba Erodii, Caulis Spatholobi, Caulis Sargentodoxae, the Rhizoma Pinelliae, Herba Taxilli, Ramulus Mori, Herba Aristolochiae, Caulis Sinomenii, Caulis Trachelospermi, Ramulus Uncariae Cum Uncis, Ramulus Cinnamomi decocts with water 2 times, amount of water is drug weight 10 times for the first time, decoct 2.5 hours, amount of water is drug weight 6 times for the second time, decoct 1.5 hours, collecting decoction, filter, filtrate is condensed into the thick paste that relative density is 1.16-1.19, add ethanol make containing alcohol amount be 70%, leave standstill 8 hours, filter, 60 ℃ of concentrating under reduced pressure of filtrate reclaim ethanol, then medicine is condensed into thick paste, 60 ℃ of drying under reduced pressure are crossed 100 mesh sieves after pulverizing, be prepared into extract powder,
(b) Pheretima, Hirudo, Scorpio, Scolopendra superfine powder are broken into the drug powder of superfine powder particle size range 5-45 μ m;
(c) drug powder that medicated powder step (a) being obtained and step (b) make mixes, and obtains middle the effective elements of the medicine of the present invention;
(d) effective ingredient of step (c) gained adds sucrose, mixes, and makes wetting agent granulate with 75% ethanol, dry, granulate, 50 bags of granulation agent, every bag heavy 3g.
Usage and dosage: each 1 bag, every day 3 times, one after each meal.Avoid pungent raw and cold diet.
Embodiment 4
Prescription:
Radix Astragali 50g, Radix Codonopsis 25g, Pheretima 7g, Hirudo 13g, Scorpio 7g, Scolopendra 13g, Herba Erodii 25g, Caulis Spatholobi 25g, Caulis Sargentodoxae 15g, Rhizoma Pinelliae 13g, Herba Taxilli 15g, Ramulus Mori 25g, Herba Aristolochiae 7g, Caulis Sinomenii 13g, Caulis Trachelospermi 7g, Ramulus Uncariae Cum Uncis 13g, Ramulus Cinnamomi 7g.
Preparation method and usage and dosage are with embodiment 1.
Embodiment 5
Prescription:
Radix Astragali 70g, Radix Codonopsis 15g, Pheretima 13g, Hirudo 7g, Scorpio 13g, Scolopendra 7g, Herba Erodii 35g, Caulis Spatholobi 15g, Caulis Sargentodoxae 25g, Rhizoma Pinelliae 7g, Herba Taxilli 25g, Ramulus Mori 10g, Herba Aristolochiae 13g, Caulis Sinomenii 7g, Caulis Trachelospermi 13g, Ramulus Uncariae Cum Uncis 7g, Ramulus Cinnamomi 13g.
Preparation method and usage and dosage are with embodiment 1.
Chinese medicine prepared by embodiment 1 has carried out clinical trial, and Details as Follows:
1. clinical data
After selecting the medical apoplexy of my institute, numb hand and foot patient 100 examples, for clinical observation object, the in the situation that of informed consent, are divided into each 50 examples for the treatment of group and matched group at random.Male 28 examples in treatment group, female's 22 examples, 42～82 years old age, average 68.6 years old, the course of disease 12 days～6 years, average 12 months.Patients with Cerebral Infarction 39 examples, patients with cerebral hemorrhage 11 examples, accompanied with hypertension 22 examples, diabetes 8 examples, hyperlipemia 17 examples, coronary heart disease 6 examples; Wherein side upper limb numbness 21 examples, side numbness of lower limbs 22 examples, both sides upper and lower extremities is numb 7 examples all; Male 29 examples in matched group, female's 21 examples; 41～82 years old age, average 67.9 years old, the course of disease 10 days～6 months, average 12 months.Patients with Cerebral Infarction 38 examples, patients with cerebral hemorrhage 12 examples; Accompanied with hypertension 23 examples, diabetes 9 examples, hyperlipemia 16 examples, coronary heart disease 5 examples; Wherein side upper limb numbness 20 examples, side numbness of lower limbs 23 examples, both sides upper and lower extremities is numb 7 examples all.Two groups at sex, age, the course of disease, coincident with severity degree of condition and accompanying diseases etc. relatively, and no significant difference (p>0.05), has comparability.The physical data difference not statistically significants such as two groups of patient ages, sex
2, diagnostic criteria:
Western medicine diagnose standard meets the diagnostic criteria that the 4th the cerebrovascular meeting in the whole nation specified, and post-stroke left over inclined to one side body numb limbs and tense tendons, with feeling cold, generate heat, be in a cold sweat, the impaired performance of Yi Hanggandeng function of nervous system.Doctor's diagnosis meets State Administration of Traditional Chinese Medicine's encephalopathy emergency case cooperative groups apoplexy in Chinese medicine diagnostic criteria in 1996.Chinese medical discrimination belongs to blood stasis due to qi deficiency, damp-phlegm resistance network type patient.Disease is seen numbness of the skin, or companion's hypalgesia, and extremity are tired heavy, heaviness of the head as if it were tightly bandaged, and loss of appetite, enlarged tongue tongue is greasy in vain, and rolling pulse is slow; Or numbness of the skin, spiritlessness and weakness, the few China of pallor, pale tongue has petechia, white and thin fur, deep-thready pulse or string are puckery.
3. Therapeutic Method
Matched group gives doctor trained in Western medicine conventional therapy, comprises brain protection, improves cerebral circulation, trophic nerve etc., and accompanied with hypertension, diabetes, coronary disease patient give blood pressure lowering, control the processing such as blood glucose and coronary dilating.Ischemic Stroke adds antiplatelet aggregation, anticoagulant therapy.
Treatment group adds Chinese medicine capsules of the present invention on matched group basis.Each 4, every day 3 times, one after each meal.Avoid pungent raw and cold diet.It within 10 days, is a course for the treatment of.After 3 courses for the treatment of, observe therapeutic outcome.
4, observation index
4.1.1 health giving quality index patient subjective symptoms, comprises numbness, pain etc., before and after treatment, patient is carried out to symptom judgement respectively once.
4.1.2 the general health check-up project of safety indexes (body temperature, blood pressure, breathing, pulse), hematuria stool routine, darling renal function inspections etc., to begin a project all before medication and clinical research finishes rear each inspection once, observe untoward reaction at any time.
4.2 statistical method total datas are all through SPSS10.0 software processes, and measurement data adopts t check, and enumeration data adopts chi-square criterion, and ranked data are checked with Ridit.
5. criterion of therapeutical effect
Criterion of therapeutical effect: determine with reference to " traditional Chinese medical science disease Standardization of diagnosis and curative effect " that national traditional Chinese medical science pharmacology office's nineteen ninety-five promulgates.Cure: all paraesthesia symptoms numb and that follow disappear completely, the numbness obstacle of having a medical check-up; Effective: pain and numbness alleviates, simultaneous phenomenon improves or alleviates, and primary symptom is still brought out unhappy emotion or impact life; Invalid: pain and numbness is unchanged, simultaneous phenomenon improve or without improvement.
6, result: the comparison of two groups of patient's curative effects, in table 1
From table l, treatment group cure rate is 44%, and total effective rate is 96%: matched group cure rate is 14%, and total effective rate is 62%.Treatment group is compared with matched group, and both curative effects have significant difference (P<O.01).Wherein in the routine patient of matched group 50,1 the course for the treatment of healing person be 5 examples, 2 the course for the treatment of healing person reach 12 examples, three courses for the treatment of, healing person reached 22 examples; In the routine patient of matched group 50,1 the course for the treatment of healing person be 0 example, 2 the course for the treatment of healing person reach 3 examples, three courses for the treatment of, healing person reached 7 examples.
| Group | Cure | Effectively | Invalid | Cure rate (%) | Total effective rate (%) |
| Treatment group (50) | 22 | 26 | 2 | 44 ** | 96 ** |
| Matched group (50) | 7 | 24 | 19 | 14 | 62 |
Note:
*with matched group comparison, P<O.01.
4.3 safety indexes are observed two groups of front and back of this clinical observation treatment general health check-up project of patient, the inspection of hematuria stool routine, cardiac inspection etc. and are had no significant change.Viewing duration, two groups there is not serious adverse events during this clinical observation.Through t check, before and after two groups of treatments, hepatic and renal function and routine blood test index of correlation are all without significant difference, and P>O.05, all has no significant effect hepatic and renal function and hemogram during pointing out two groups of medications.
Claims (7)
1. a Chinese medicine for the treatment of numb limbs and tense tendons after apoplexy, is characterized in that, is made up of the raw material of Chinese medicine medicine of following weight portion:
Radix Astragali 50-70 part, Radix Codonopsis 15-25 part, Pheretima 7-13 part, Hirudo 7-13 part, Scorpio 7-13 part, Scolopendra 7-13 part, Herba Erodii 25-35 part, Caulis Spatholobi 15-25 part, Caulis Sargentodoxae 15-25 part, Rhizoma Pinelliae 7-13 part, Herba Taxilli 15-25 part, Ramulus Mori 10-25 part, Herba Aristolochiae 7-13 part, Caulis Sinomenii 7-13 part, Caulis Trachelospermi 7-13 part, Ramulus Uncariae Cum Uncis 7-13 part, Ramulus Cinnamomi 7-13 part.
2. the Chinese medicine of numb limbs and tense tendons after treatment apoplexy according to claim 1, is characterized in that, is made up of the raw material of Chinese medicine medicine of following weight portion:
Radix Astragali 55-65 part, Radix Codonopsis 17-23 part, Pheretima 8-12 part, Hirudo 8-12 part, Scorpio 8-12 part, Scolopendra 8-12 part, Herba Erodii 27-33 part, Caulis Spatholobi 17-23 part, Caulis Sargentodoxae 17-23 part, Rhizoma Pinelliae 8-12 part, Herba Taxilli 17-23 part, Ramulus Mori 12-18 part, Herba Aristolochiae 8-12 part, Caulis Sinomenii 8-12 part, Caulis Trachelospermi 8-12 part, Ramulus Uncariae Cum Uncis 8-12 part, Ramulus Cinnamomi 8-12 part.
3. the Chinese medicine of numb limbs and tense tendons after treatment apoplexy according to claim 2, is characterized in that, is made up of the raw material of Chinese medicine medicine of following weight portion:
60 parts of the Radixs Astragali, 20 parts of Radix Codonopsis, 10 parts of Pheretimas, 10 parts of Hirudos, 10 parts of Scorpios, 10 parts of Scolopendras, 30 parts of Herba Erodiis, 20 parts of Caulis Spatholobis, 20 parts of Caulis Sargentodoxae, 10 parts of the Rhizoma Pinelliaes, 20 parts of Herba Taxillis, 15 parts of Ramulus Moris, 10 parts of Herba Aristolochiaes, 10 parts of Caulis Sinomeniis, 10 parts of Caulis Trachelospermis, 10 parts of Ramulus Uncariae Cum Uncis, 10 parts of Ramulus Cinnamomi.
4. according to the Chinese medicine of numb limbs and tense tendons after the treatment apoplexy described in claim 1 or 2 or 3, it is characterized in that, the dosage form of this Chinese medicine is oral formulations.
5. the Chinese medicine of numb limbs and tense tendons after treatment apoplexy according to claim 4, is characterized in that, the dosage form of this Chinese medicine is capsule, tablet.
6. the preparation method of the Chinese medicine of numb limbs and tense tendons after the treatment apoplexy described in claim 1 or 2 or 3, comprises the steps:
(a) Radix Astragali, Radix Codonopsis, Herba Erodii, Caulis Spatholobi, Caulis Sargentodoxae, the Rhizoma Pinelliae, Herba Taxilli, Ramulus Mori, Herba Aristolochiae, Caulis Sinomenii, Caulis Trachelospermi, Ramulus Uncariae Cum Uncis, Ramulus Cinnamomi decocts with water 2 times, the 8-10 that amount of water is drug weight for the first time doubly, decoct 1.5-2.5 hour, the 4-6 that amount of water is drug weight for the second time doubly, decoct 1-2 hour, collecting decoction, filter, filtrate is condensed into the thick paste that relative density is 1.16-1.19, add ethanol make containing alcohol amount be 70%, leave standstill 8 hours, filter, 60 ℃ of concentrating under reduced pressure of filtrate reclaim ethanol, then medicine is condensed into thick paste, 60 ℃ of drying under reduced pressure are crossed 100 mesh sieves after pulverizing, be prepared into extract powder,
(b) Pheretima, Hirudo, Scorpio, Scolopendra superfine powder are broken into the drug powder of superfine powder particle size range 5-45 μ m;
(c) drug powder that medicated powder step (a) being obtained and step (b) make mixes, and obtains middle the effective elements of the medicine of the present invention;
(d) effective ingredient of step (c) gained adds pharmaceutically acceptable adjuvant to make preparation.
7. the preparation method of the Chinese medicine of numb limbs and tense tendons after treatment apoplexy according to claim 6, it is characterized in that, in described step (a), amount of water is drug weight 9 times for the first time, decocts 2 hours, amount of water is drug weight 5 times for the second time, decocts 1.5 hours.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410046040.XA CN103768307B (en) | 2014-02-10 | 2014-02-10 | Traditional Chinese medicine for treating post-stroke limb numbness and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410046040.XA CN103768307B (en) | 2014-02-10 | 2014-02-10 | Traditional Chinese medicine for treating post-stroke limb numbness and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103768307A true CN103768307A (en) | 2014-05-07 |
| CN103768307B CN103768307B (en) | 2017-02-01 |
Family
ID=50561367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410046040.XA Active CN103768307B (en) | 2014-02-10 | 2014-02-10 | Traditional Chinese medicine for treating post-stroke limb numbness and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103768307B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105853508A (en) * | 2016-05-25 | 2016-08-17 | 刘猛 | Traditional Chinese medicine composition for treating cold and cool numbness of hands and feet and preparation method thereof |
| CN106138410A (en) * | 2016-08-12 | 2016-11-23 | 泰山医学院附属医院 | Chinese medicine composition and the device for fumigation of numb limbs and tense tendons after apoplexy is treated based on stifling mode |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1726966A (en) * | 2005-07-27 | 2006-02-01 | 咸阳步长医药科技发展有限公司 | Preparation of oral disintegration tablet in use for treating disease of apoplexy and obstruction of qi in the chest |
| CN1872187A (en) * | 2005-06-03 | 2006-12-06 | 天津天士力制药股份有限公司 | Application of medication composition of containing astragalus root in preparing medication for treating chronic insufficiency of supplying blood for brain |
| US20110250183A1 (en) * | 2008-11-10 | 2011-10-13 | Moleac Pte. Ltd. | Combination Therapy for Treatment of Patients with Neurological Disorders and Cerebral Infarction |
-
2014
- 2014-02-10 CN CN201410046040.XA patent/CN103768307B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1872187A (en) * | 2005-06-03 | 2006-12-06 | 天津天士力制药股份有限公司 | Application of medication composition of containing astragalus root in preparing medication for treating chronic insufficiency of supplying blood for brain |
| CN1726966A (en) * | 2005-07-27 | 2006-02-01 | 咸阳步长医药科技发展有限公司 | Preparation of oral disintegration tablet in use for treating disease of apoplexy and obstruction of qi in the chest |
| US20110250183A1 (en) * | 2008-11-10 | 2011-10-13 | Moleac Pte. Ltd. | Combination Therapy for Treatment of Patients with Neurological Disorders and Cerebral Infarction |
Non-Patent Citations (2)
| Title |
|---|
| 吴萍等: "补阳还五汤加味治疗气虚血瘀型中风后遗症疗效观察", 《上海中医药杂志》 * |
| 黄雄等: "出血性中风恢复期及后遗症中医药治疗的研究进展", 《中西医结合心脑血管病杂志》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105853508A (en) * | 2016-05-25 | 2016-08-17 | 刘猛 | Traditional Chinese medicine composition for treating cold and cool numbness of hands and feet and preparation method thereof |
| CN106138410A (en) * | 2016-08-12 | 2016-11-23 | 泰山医学院附属医院 | Chinese medicine composition and the device for fumigation of numb limbs and tense tendons after apoplexy is treated based on stifling mode |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103768307B (en) | 2017-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100353983C (en) | Chinese medicine preparation for reducing sugar | |
| CN1325083C (en) | Medicinal composition for removing dampness to relieve itching and its preparation method and uses | |
| CN102178800B (en) | Chinese medicine composition for treating rheumatoid arthritis and preparation method thereof | |
| CN101773551B (en) | External-use medicine composition of traditional Mongolian medicine for curing soft tissue injury | |
| CN101632750B (en) | Chinese medicinal composition for replenishing essence, filling marrow, boosting kidney and strengthening yang and preparation method thereof | |
| CN102166278A (en) | Chinese medicinal composition for treating pediatric rheumatoid arthritis and preparation method thereof | |
| CN102772712B (en) | Traditional Chinese medicine composition for treating heat-toxicity, flourishing and blood stasis type diabetic foot | |
| CN103768307B (en) | Traditional Chinese medicine for treating post-stroke limb numbness and preparation method thereof | |
| CN114767824B (en) | Preparation for treating laryngeal cough and preparation method thereof | |
| CN100364565C (en) | Chinese medicine composition for treating apoplexy and its preparing method | |
| CN102552520B (en) | Blood circulation-promoting and pain-stopping medicament and preparation process and application thereof | |
| CN102580030B (en) | External traditional Chinese medicine composition having effect of reducing blood sugar, preparation prepared from the external traditional Chinese medicine composition, and their preparation method | |
| CN108465061A (en) | It is a kind of to be used to treat pharmaceutical composition of Facial Recurrent Dermatitis and its preparation method and application | |
| CN112138084B (en) | Traditional Chinese medicine composition for treating bronchiectasis qi-yin deficiency and phlegm-heat obstructing lung and application thereof | |
| CN104524247A (en) | Pharmaceutical composition for treating migraine and application thereof | |
| CN103735793B (en) | A kind ofly treat Chinese medicine of numb limbs and tense tendons after diabetes patient's apoplexy and preparation method thereof | |
| CN102949689A (en) | Traditional Chinese medicine preparation for treating spontaneous perspiration and leaking sweat | |
| CN101732425B (en) | Externally-applied medicine composite for psoriasis | |
| CN104644946A (en) | Traditional Chinese medicine preparation for treating lower-limb ulcer and preparation method thereof | |
| CN104367896B (en) | A kind of pharmaceutical composition for treating Qi deficiency blood stasis type apoplexy and preparation method thereof | |
| CN109331152A (en) | A kind of Chinese medicine composition for treating vasculitis | |
| CN103768454A (en) | Composition for preventing and treating HIV/AIDS (Human Immunodeficiency Virus/ Acquired Immune Deficiency Syndrome) and preparation method thereof | |
| CN102552841A (en) | Traditional Chinese medicine for treating apoplexy sequelae | |
| CN105687499A (en) | Betaxolol containing pharmaceutical composition for treating hypertension and preparation method thereof | |
| CN207125908U (en) | For coronary disease and angina pectoris paster |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP02 | Change in the address of a patent holder |
Address after: 262100 North Head East of Light Source Road, Taierzhuang Economic Development Zone, Zaozhuang City, Shandong Province Patentee after: Gao Feng Address before: 262100 Anqiu People's Hospital, No. 246 Health Road, Anqiu City, Weifang City, Shandong Province Patentee before: Gao Feng |
|
| CP02 | Change in the address of a patent holder | ||
| CP02 | Change in the address of a patent holder |
Address after: 262100 Anqiu People's Hospital, No. 246 Health Road, Anqiu City, Weifang City, Shandong Province Patentee after: Gao Feng Address before: 262100 North Head East of Light Source Road, Taierzhuang Economic Development Zone, Zaozhuang City, Shandong Province Patentee before: Gao Feng |
|
| CP02 | Change in the address of a patent holder | ||
| CP02 | Change in the address of a patent holder |
Address after: 236000 room 1401, unit 5, building 8, Baorui Kaixuan City, Yougang Road, Yingshang County, Fuyang City, Anhui Province Patentee after: Gao Feng Address before: 262100 Anqiu people's Hospital, 246 health Road, Shandong, Weifang, Anqiu Patentee before: Gao Feng |
|
| CP02 | Change in the address of a patent holder | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200612 Address after: 363000 No.16, Weihui Road, Suian Industrial Zone, Zhangpu County, Zhangzhou City, Fujian Province Patentee after: Fujian tongyitangguo Pharmaceutical Development Co.,Ltd. Address before: 236000 room 1401, unit 5, building 8, Baorui Kaixuan City, Yougang Road, Yingshang County, Fuyang City, Anhui Province Patentee before: Gao Feng |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220512 Address after: 343000 No. 283, Jingjiu Avenue, Jinggangshan economic and Technological Development Zone, Ji'an City, Jiangxi Province Patentee after: JIANGXI KANGZHIKANG APPARATUS CO.,LTD. Address before: 363000 No.16, Weihui Road, sui'an Industrial Zone, Zhangpu County, Zhangzhou City, Fujian Province Patentee before: Fujian tongyitangguo Pharmaceutical Development Co.,Ltd. |
|
| TR01 | Transfer of patent right |